NPM1 and acute myeloid leukemia: Cytogenetics together with mutation status of NPM1, CEBPA, and FLT3 internal tandem duplications (FLT3-ITD) form the basis of the European LeukemiaNet (ELN) risk classification system [4], which provides means for risk stratification of AML patients.